ValiRx PLC (LON:VAL) has hailed the publication of its first peer-reviewed article assessing clinical trial results for its cancer drug VAL401.
Data from the Phase II study, completed last year in Tbilisi, Georgia, will be carried in the European Journal of Drug Metabolism and Pharmacokinetics.
READ: ValiRx’s VAL201 records “statistically significant” response in clinical trial
The report is intended to be the first in a series of results-based publications on the treatment, said Dr Suzy Dilly, chief executive of ValiSeek, the joint-venture company developing VAL401.
“Peer-reviewed publications are always interesting to complete, as the article is very much shaped and expanded by the anonymous expert reviewers, providing a respected validation of the data," she added.
VAL401 is a new formulation of the antipsychotic drug risperidone, which researchers have transformed into a potential oncology treatment.
The analysis carried in the industry publication considers the clinical significance of the trial results in comparison to previously-reported data for conventional risperidone, “providing theoretical insight into the altered activity of the therapeutic”.
New cash injection
Separately, the company said it had raised £500,000 through the issue of shares at 0.75p each. The proceeds will be used to “further expand the scope” of the clinical trial of VAL201, which is being developed to treat prostate cancer. ValiRx shares held above that placing level at 0.80p.
By doing this, it hopes the drug candidate will “more speedily reach its full therapeutic potential and potential anti-cancer impact”.
The cash injection will also be used to progress the development of the pre-clinical programmes VAL301 and VAL101.
-- Adds placing details, share price --